1	UNITED STATES DISTRICT COURT
2	NORTHERN DISTRICT OF NEW YORK
3	
4	NOVARTIS PHARMA AG, et al.,
5)) Plaintiffs,) CASE NO. 20-CV-690
6	
7	vs.)
8	REGENERON PHARMACEUTICALS, INC.,)
9	Defendant.)
10	TRANSCRIPT OF PROCEEDINGS
11	BEFORE THE HON. CHRISTIAN F. HUMMEL WEDNESDAY, AUGUST 18, 2021
12	ALBANY, NEW YORK
13	FOR THE PLAINTIFFS: BOND SCHOENECK & KING, PLLC
14	By: GEORGE R. MCGUIRE, ESQ. One Lincoln Center
15	Syracuse, New York 13202
16	GOODWIN PROCTER LLP
17	By: ELIZABETH J. HOLLAND, ESQ. and MOLLY R. GRAMMEL, ESQ. 620 Eighth Avenue
18	New York, New York 10018
19	FOR THE DEFENDANT:
20	BARCLAY DAMON LLP By: DOUGLAS J. NASH, ESQ.
21	125 East Jefferson Street Syracuse, New York 13202
22	WEIL GOTSHAL & MANGES LLP
23	BY: ANISH R. DESAI, ESQ. 767 Fifth Avenue
24	New York, New York 10153
25	
د ک	



 ${\it JACQUELINE~STROFFOLINO\,,~RPR}$

1	(Open court.)
2	THE CLERK: Today is Wednesday, August 18, 2021,
3	10:31 a.m. The case is Novartis Pharma AG et al. versus
4	Regeneron Pharmaceuticals, Inc., docket No. 20-CV-690. May we
5	have appearances for the record.
6	MR. MCGUIRE: George McGuire for Bond, Schoeneck &
7	King, Your Honor, for plaintiffs.
8	THE COURT: Good morning, Mr. McGuire.
9	MS. HOLLAND: Good morning, Your Honor. Elizabeth
10	Holland of Goodwin Procter for Novartis plaintiffs.
11	THE COURT: Good morning, Ms. Holland.
12	MS. GRAMMEL: Good morning, Your Honor. Molly
13	Grammel, Goodwin Procter for Novartis as well.
14	THE COURT: Good morning, Ms. Grammel.
15	MR. NASH: Your Honor, Doug Nash from Barclay Damon
16	for Regeneron.
17	THE COURT: Good morning, Mr. Nash.
18	MR. DESAI: Good morning, Your Honor. Anish Desai
19	here on behalf of the Regeneron.
20	THE COURT: Good morning, Mr. Desai.
21	Are there additional counsel appearing by phone this
22	morning?
23	MS. HOLLAND: No, Your Honor. We have clients on the
24	phone who are counsel.
25	THE COURT: That's fine. Do you wish them to note



1.3

2.0

2.3

their appearance, or are you happy with the three of you?

MS. HOLLAND: I'm happy, but I'm happy to introduce
them as well. I believe we have Cynthia Lopez, Peter Waibel,
and Michelle Kitchen from Novartis legal department.

THE COURT: Good morning, counselors.

In addition, folks -- let me back up. I'm Judge

Hummel. I'm one of the magistrate judges. In addition, we had

a call from a member of the public who indicated they may wish

to call in this morning. I think my courtroom deputy,

Ms. Burtt, advised you of that. Because we're conducting this

in open court and on the record, it's a public proceeding. So

the public has the right to appear.

Secondly, as you know, you may know, here in the Northern District, we've adopted a mask requirement in the public airways, but not in here. You're welcome to keep your masks off. I presume if you've taken your mask off, you're fully vaccinated. I'm fully vaccinated to the extent you wanted to know that. So it's not my intention to wear a mask. If at some point someone feels uncomfortable, they're welcome to do so.

I've had an opportunity to review the civil case management plan which was submitted with respect to this matter, which is docket No. 73, which was 24 pages in length. I've also reviewed the exhibits which are annexed to that document, which appear among other places at docket No. 73-1 and 73-2, 73-1



1.3

2.0

2.3

being a comparison of the proposed case schedules set forth for the plaintiff Novartis and defendant Regeneron with respect to this matter.

Before we get into the specifics of the order, let me just advise you that it is not my intention to redo discovery that was done in the Southern District of New York or may have been done somewhere else. To the extent that discovery is done, has been done, I assume you folks will take steps to make certain that it can be used here. So to the extent that people were deposed in the ITC proceeding or in the Southern District, we're not going to reinvent the wheel or redo all of that discovery. Having discussed this matter with another member of the judiciary, we want to move this matter forward in an expeditious but fair fashion.

Having said that, I'm going to go through docket

No. 73-1, which contains the proposed schedules. And then to

the extent I wish to hear from someone with respect to a

particular issue, I'll give each attorney an opportunity or each

side the opportunity to be heard with respect to that.

If you go down to docket No. 73-1, beginning with patentee infringement contentions, there seems to be agreement those will be filed by September 1 of 2021.

You then go to the civil case management plan, which is docket No. 73. With respect to joinder of parties and amendment of pleadings, I'm going to direct that any such



1.3

2.3

applications for joinder of parties be made by September 15 of 2021. With respect to the next item, accused noninfringement, invalidity, unenforceability contentions, I'm going to direct those be filed by September 22 of 2021.

And I should note we will do an order containing all of these matters when it's done, but I wanted to give you these today.

The next dispute involves the necessity or the need for claims construction in this matter. We're not going to redo claims construction which may have been done in the ITC or in the Southern District. However, Regeneron contends that there are additional claims construction which needs to be done.

I guess I'll hear from Regeneron first and give someone from Novartis a chance to be heard. Who would like to speak on behalf of the issue of the need for additional claims construction?

MR. DESAI: Your Honor, I'll speak to that.

THE COURT: Go ahead, Counselor.

MR. DESAI: So in the ITC case, there was a claim construction hearing, and then -- but unfortunately because the way the ITC works, it does not allow us I believe to skip claim construction here in the district court. And the reason being the ITC proceedings are conducted as bench trials, and it is frequently the case --

THE REPORTER: Can you slow down, please.



DOCKET

Explore Litigation Insights



Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time** alerts and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.

